Ruhi Ahmad Khan Sells 6,938 Shares of Caribou Biosciences (NASDAQ:CRBU) Stock

Caribou Biosciences, Inc. (NASDAQ:CRBU) insider Ruhi Ahmad Khan sold 6,938 shares of the company’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $1.96, for a total value of $13,598.48. Following the completion of the sale, the insider owned 104,998 shares in the company, valued at approximately $205,796.08. This represents a 6.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Caribou Biosciences Price Performance

Caribou Biosciences stock opened at $1.95 on Thursday. The business has a 50 day simple moving average of $1.62 and a 200 day simple moving average of $1.90. The company has a market capitalization of $182.27 million, a PE ratio of -1.15 and a beta of 2.61. Caribou Biosciences, Inc. has a one year low of $0.66 and a one year high of $3.54.

Institutional Investors Weigh In On Caribou Biosciences

A number of hedge funds have recently added to or reduced their stakes in CRBU. R Squared Ltd acquired a new stake in Caribou Biosciences in the 3rd quarter valued at about $29,000. Bronte Capital Management Pty Ltd. acquired a new position in shares of Caribou Biosciences during the fourth quarter worth approximately $25,000. Liberty Wealth Management LLC bought a new stake in shares of Caribou Biosciences during the third quarter valued at approximately $45,000. Next Capital Management LLC acquired a new stake in shares of Caribou Biosciences in the second quarter valued at approximately $25,000. Finally, Creative Planning acquired a new stake in shares of Caribou Biosciences in the second quarter valued at approximately $25,000. Institutional investors own 77.51% of the company’s stock.

Analysts Set New Price Targets

CRBU has been the topic of several analyst reports. Truist Financial set a $7.00 target price on shares of Caribou Biosciences in a report on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Wednesday, January 21st. Citigroup raised their price objective on shares of Caribou Biosciences from $5.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 3rd. Finally, HC Wainwright lifted their target price on shares of Caribou Biosciences from $3.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.00.

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.